 Patients with metastatic colorectal cancer are living longer and running out of therapeutic options due to disease resistance. Epidermal growth factor receptor EGFR has been validated as a therapeutic target in colorectal cancer CRC. Ligand binding to EGFR activates the RASRAFMAPK, STAT, and PI3KAKT signaling pathways, which together modulate cellular proliferation, adhesion, migration, and survival. Anti-EGFR targeted antibodies cetuximab and panitumumab administered as monotherapy in CRC have shown response rates of approximately 9 and 17 respectively Amado et al., 2008; Saltz et al., 2004. Single agent panitumumab has been approved for use in third line colorectal cancer and has been shown improve progression free survival over supportive care. Further subset analysis showed the response rate of 17 was confined to patients with KRAS wild type tumors only and that this group approximately 60-70 of all CRC patients should be considered for further study Amado et al., 2008. According to the Huntsman Cancer Hospital registry, colorectal cancer patients are the largest disease group within our gastrointestinal cancer group and many have or eventually will progress on available therapy or are or will become intolerant to the side effects of second line therapies such as oxaliplatin neuropathy or irinotecan induced diarrhea, yet still are candidates for treatment. 